Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance.

Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge JS.

Cancer Cell. 2018 Jun 11;33(6):985-1003.e7. doi: 10.1016/j.ccell.2018.05.001. Epub 2018 May 24.

PMID:
29805077
2.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC.

Cell Rep. 2017 Dec 5;21(10):2796-2812. doi: 10.1016/j.celrep.2017.11.022.

3.

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K.

Cancer Res. 2017 Nov 1;77(21):5706-5711. doi: 10.1158/0008-5472.CAN-17-1789. Epub 2017 Oct 9. Review.

PMID:
28993414
4.

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K.

Cancer Discov. 2017 Dec;7(12):1450-1463. doi: 10.1158/2159-8290.CD-17-0177. Epub 2017 Sep 29.

PMID:
28963352
5.

Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.

Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski K.

Cancer Discov. 2017 Feb;7(2):202-217. doi: 10.1158/2159-8290.CD-16-0520. Epub 2016 Dec 14.

6.

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF, Hammerman PS, Brown M, Cichowski K, Long H, Bradner JE, Wong KK.

Cancer Discov. 2016 Sep;6(9):1006-21. doi: 10.1158/2159-8290.CD-16-0164. Epub 2016 Jun 16.

7.

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.

Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E, Konicek BM, Yan SC, Graff JR, Cichowski K.

J Clin Invest. 2016 Jun 1;126(6):2181-90. doi: 10.1172/JCI85183. Epub 2016 May 9.

8.

Loss of negative regulators amplifies RAS signaling.

Lock R, Cichowski K.

Nat Genet. 2015 May;47(5):426-7. doi: 10.1038/ng.3299.

PMID:
25916896
9.

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.

Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.

10.

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K.

Nature. 2014 Oct 9;514(7521):247-51. doi: 10.1038/nature13561. Epub 2014 Aug 13.

PMID:
25119042
11.

Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.

Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K.

Cancer Discov. 2014 Sep;4(9):1062-73. doi: 10.1158/2159-8290.CD-14-0159. Epub 2014 Jun 9.

12.

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.

Maertens O, Cichowski K.

Adv Biol Regul. 2014 May;55:1-14. doi: 10.1016/j.jbior.2014.04.002. Epub 2014 Apr 30. Review.

PMID:
24814062
13.

Paths of resistance to EGFR inhibitors: is NF enough?

Maertens O, Cichowski K.

Cancer Discov. 2014 May;4(5):519-21. doi: 10.1158/2159-8290.CD-14-0286.

14.

Setting the stage for successful oral feeding: the impact of implementing the SOFFI feeding program with medically fragile NICU infants.

Horner S, Simonelli AM, Schmidt H, Cichowski K, Hancko M, Zhang G, Ross ES.

J Perinat Neonatal Nurs. 2014 Jan-Mar;28(1):59-68. doi: 10.1097/JPN.0000000000000003.

PMID:
24476653
15.

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H.

Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17.

16.

The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C, Cichowski K.

Cancer Cell. 2013 Sep 9;24(3):365-78. doi: 10.1016/j.ccr.2013.08.004.

17.

Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras.

Hollstein PE, Cichowski K.

Cancer Discov. 2013 Aug;3(8):880-93. doi: 10.1158/2159-8290.CD-13-0146. Epub 2013 May 9.

18.

Elucidating distinct roles for NF1 in melanomagenesis.

Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K.

Cancer Discov. 2013 Mar;3(3):338-49. doi: 10.1158/2159-8290.CD-12-0313. Epub 2012 Nov 21.

19.

SPRED proteins provide a NF-ty link to Ras suppression.

McClatchey AI, Cichowski K.

Genes Dev. 2012 Jul 15;26(14):1515-9. doi: 10.1101/gad.197434.112.

20.

Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, Pan D, Stemmer-Rachamimov A, Upadhyaya M, Viskochil D, Wallace MR, Hunter-Schaedle K, Ratner N.

Acta Neuropathol. 2012 Mar;123(3):369-80. doi: 10.1007/s00401-011-0905-0. Epub 2011 Nov 16.

21.

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, Legius E.

Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24.

PMID:
21987445
22.

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K.

Cancer Cell. 2011 Sep 13;20(3):400-13. doi: 10.1016/j.ccr.2011.08.014.

23.

Back to the future: proceedings from the 2010 NF Conference.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.

Am J Med Genet A. 2011 Feb;155A(2):307-21. doi: 10.1002/ajmg.a.33804. Epub 2010 Dec 22.

24.

Drug discovery: inhibitors that activate.

Cichowski K, Jänne PA.

Nature. 2010 Mar 18;464(7287):358-9. doi: 10.1038/464358a. No abstract available.

PMID:
20237552
25.

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K.

Nat Med. 2010 Mar;16(3):286-94. doi: 10.1038/nm.2100. Epub 2010 Feb 14.

26.

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K.

Cancer Cell. 2009 Jul 7;16(1):44-54. doi: 10.1016/j.ccr.2009.05.009.

27.

Unexpected pieces to the senescence puzzle.

Cichowski K, Hahn WC.

Cell. 2008 Jun 13;133(6):958-61. doi: 10.1016/j.cell.2008.05.027. Review.

28.

Many roads lead to oncogene-induced senescence.

Courtois-Cox S, Jones SL, Cichowski K.

Oncogene. 2008 May 1;27(20):2801-9. doi: 10.1038/sj.onc.1210950. Epub 2008 Jan 14. Review.

PMID:
18193093
29.

TORC1 is essential for NF1-associated malignancies.

Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K.

Curr Biol. 2008 Jan 8;18(1):56-62. doi: 10.1016/j.cub.2007.11.066. Epub 2007 Dec 27.

30.

A negative feedback signaling network underlies oncogene-induced senescence.

Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K.

Cancer Cell. 2006 Dec;10(6):459-72.

31.

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8. Epub 2005 Jun 3. Erratum in: Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16119.

32.

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93. Epub 2005 Feb 24.

33.

Comparative pathology of nerve sheath tumors in mouse models and humans.

Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.

Cancer Res. 2004 May 15;64(10):3718-24.

34.

Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.

Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T.

Genes Dev. 2003 Feb 15;17(4):449-54.

35.

Mouse models of neurofibromatosis.

McClatchey AI, Cichowski K.

Biochim Biophys Acta. 2001;1471(2):M73-80. Review. No abstract available.

PMID:
11342186
36.

NF1 tumor suppressor gene function: narrowing the GAP.

Cichowski K, Jacks T.

Cell. 2001 Feb 23;104(4):593-604. Review. No abstract available.

37.

Dysphagia after head trauma: the effect of cognitive-communicative impairments on functional outcomes.

Halper AS, Cherney LR, Cichowski K, Zhang M.

J Head Trauma Rehabil. 1999 Oct;14(5):486-96.

PMID:
10653944
38.

Mouse models of tumor development in neurofibromatosis type 1.

Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T.

Science. 1999 Dec 10;286(5447):2172-6.

39.

PAR1 activation initiates integrin engagement and outside-in signalling in megakaryoblastic CHRF-288 cells.

Cichowski K, Orsini MJ, Brass LF.

Biochim Biophys Acta. 1999 Jul 8;1450(3):265-76.

40.

K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T.

Genes Dev. 1997 Oct 1;11(19):2468-81. Erratum in: Genes Dev 1997 Dec 1;11(23):3277.

41.

Signaling through G proteins in platelets: to the integrins and beyond.

Brass LF, Manning DR, Cichowski K, Abrams CS.

Thromb Haemost. 1997 Jul;78(1):581-9. Review.

PMID:
9198220
42.

Nf1 gene targeting: toward models and mechanisms.

Cichowski K, Shih TS, Jacks T.

Semin Cancer Biol. 1996 Oct;7(5):291-8. Review.

PMID:
9110406
44.
45.

Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides.

Vassallo RR Jr, Kieber-Emmons T, Cichowski K, Brass LF.

J Biol Chem. 1992 Mar 25;267(9):6081-5.

46.

p21rasGAP association with Fyn, Lyn, and Yes in thrombin-activated platelets.

Cichowski K, McCormick F, Brugge JS.

J Biol Chem. 1992 Mar 15;267(8):5025-8.

47.

Increased assembly of clathrin occurs in response to mitogenic activation of murine lymphocytes.

Corvera S, Bartels JL, Capocasale RJ, Cichowski K, Moore JS.

J Biol Chem. 1989 Jul 25;264(21):12568-72.

48.

Multivariate analysis of improvement and outcome following stroke rehabilitation.

Heinemann AW, Roth EJ, Cichowski K, Betts HB.

Arch Neurol. 1987 Nov;44(11):1167-72.

PMID:
3675249

Supplemental Content

Loading ...
Support Center